Here, we demonstrate that treatment with a bispecific Clec9A-PDL1 targeted AcTaferon induces tumor control accompanied with changes at the level of various cell types including myeloid cells, DCs, antigen-specific CTLs, increased presence of NK and NKT cells as well as decrease of tumor-resident Tregs. This evidence concerns the gene CD274 and neoplasm.